DEDICATED HEALTHCARE EXPERTS Our global and regional team of technical specialists provide support for multiple projects including global transfers, troubleshooting, and developing the right solution for each need. APPLICATION PORTFOLIO DESCRIPTION General use Opaque and transparent colors in PP, PE, COC, ABS, POM, PC, TPU, PEEK, and more Needle hubs and cannulae Opaque and translucent colors evaluated to ISO 6009 Ophthalmic caps and closures 13 standard colors in PE matched to American Academy of Ophthalmology; biologically evaluated to USP standard White pharmaceutical packaging White colorants for PE, HDPE, PP covering solid dose to nasal packaging needs Amber pharmaceutical packaging Pre-tested amber colorants LSR silicones For LSR silicones and transparent color PET/PP (e.g. amber) FUNCTIONALITY ADDITIVE PERFORMANCE UV protection in transparent packaging Blocks UV in 290–450nm for PP, PE, PETG, COP Processing aid/friction reduction Optimizes processing for PE, PP, ABS, POM—non-migrating Nucleation for reduced material consumption/cycle time Improves thermal and mechanical properties of PE and PP and allows wall thinning to support sustainability Clarifying Improves clarity of transparent PP applications with reduced migration and improved thermal stability—sorbitol-free Laser marking/welding Activates the polymer to absorb Nd-YAG laser for fast reliable marking/assembly Gamma/e-beam sterilization Preserves the properties of PP and COP, reduces yellowing and compensates for discoloration Anti-static Reduces static buildup in applications such as films in API handling and inhaler spacers/nebulizers Antioxidant Provides thermal protection during converting/ downstream sterilization Anti-counterfeit/brand protection Covert and non-covert systems SUPPORTING SUSTAINABILITY TARGETS As the need to integrate sustainability in the design of healthcare products is growing, manufacturers of medical devices, diagnostic products and pharmaceutical packaging are looking for materials with a more environmentally friendly profile.

As the largest acquisition in our history, it was important that we get it right, and we have. Financing Activities Net cash used by financing activities in 2021 primarily reflects $77.7 million in dividends paid and the repayment of long term debt of $18.5 million. 3) In addition to options, warrants and rights, the the 2020 EICP authorizes the issuance of restricted stock, RSUs and performance shares.

Buyer shall have no right of set-off. Buyer agrees to indemnify and hold harmless Seller from and against any liability (including fines or legal fees) incurred by Seller with respect to any export or re-export activities by Buyer in violation of its obligations under the applicable laws. Within 10 (ten) days after receipt of such notice, Seller may exercise its right to terminate the sale contract by giving Buyer written notice.

2) Tax adjustments include the net tax benefit/(expense) from one-time income tax items, the set-up or reversal of uncertain tax position reserves and deferred income tax valuation allowance adjustments. 8 Attachment 4 Avient Corporation Condensed Consolidated Balance Sheets (In millions) (Unaudited) March 31, 2022 December 31, 2021 ASSETS Current assets: Cash and cash equivalents $ 562.6 $ 601.2 Accounts receivable, net 757.9 642.3 Inventories, net 475.4 461.1 Other current assets 131.0 122.4 Total current assets 1,926.9 1,827.0 Property, net 661.9 676.1 Goodwill 1,283.4 1,286.4 Intangible assets, net 904.1 925.2 Operating lease assets, net 67.1 74.1 Other non-current assets 200.3 208.4 Total assets $ 5,043.7 $ 4,997.2 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Short-term and current portion of long-term debt $ 607.5 $ 8.6 Accounts payable 642.3 553.9 Current operating lease obligations 21.7 24.2 Accrued expenses and other current liabilities 284.8 353.9 Total current liabilities 1,556.3 940.6 Non-current liabilities: Long-term debt 1,250.2 1,850.3 Pension and other post-retirement benefits 98.5 100.0 Deferred income taxes 99.4 100.6 Non-current operating lease obligations 45.9 50.1 Other non-current liabilities 164.1 165.1 Total non-current liabilities 1,658.1 2,266.1 SHAREHOLDERS' EQUITY Avient shareholders’ equity 1,813.2 1,774.7 Noncontrolling interest 16.1 15.8 Total equity 1,829.3 1,790.5 Total liabilities and equity $ 5,043.7 $ 4,997.2 9 Attachment 5 Avient Corporation Condensed Consolidated Statements of Cash Flows (Unaudited) (In millions) Three Months Ended March 31, 2022 2021 Operating Activities Net income $ 84.5 $ 79.7 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 35.7 36.6 Accelerated depreciation and amortization 2.1 0.5 Share-based compensation expense 3.2 2.7 Changes in assets and liabilities, net of the effect of acquisitions: Increase in accounts receivable (118.8) (137.6) Increase in inventories (15.1) (35.1) Increase in accounts payable 90.5 67.3 Decrease in pension and other post-retirement benefits (4.0) (7.1) Decrease in accrued expenses and other assets and liabilities, net (59.2) (3.4) Net cash provided by operating activities 18.9 3.6 Investing activities Capital expenditures (13.3) (16.5) Other investing activities — (2.0) Net cash used by investing activities (13.3) (18.5) Financing activities Purchase of common shares for treasury (15.8) (4.2) Cash dividends paid (21.7) (19.5) Repayment of long-term debt (2.4) (2.3) Payments of withholding tax on share awards (3.9) (3.1) Net cash used by financing activities (43.8) (29.1) Effect of exchange rate changes on cash (0.4) (11.0) Decrease in cash and cash equivalents (38.6) (55.0) Cash and cash equivalents at beginning of year 601.2 649.5 Cash and cash equivalents at end of period $ 562.6 $ 594.5 10 Attachment 6 Avient Corporation Business Segment Operations (Unaudited) (In millions) Operating income and earnings before interest, taxes, depreciation and amortization (EBITDA) at the segment level does not include: special items as defined in Attachment 3; corporate general and administration costs that are not allocated to segments; intersegment sales and profit eliminations; share-based compensation costs; and certain other items that are not included in the measure of segment profit and loss that is reported to and reviewed by the chief operating decision maker.

plastics) stigmatized Rising expectations for rapid innovation and displacement of older, heavily carbon- intensive designs and manufacturing processes NDC countries expected to innovate and seek rapid minimization of customers' scope 3 emissions Increased concern from stakeholders for not addressing climate change globally or for the chemicals sector Acute & Chronic Risk Possible direct damage to fixed assets and logistics disruptions in both our value chain and operations More frequent and intense weather events and changing preciptation patterns are likely to damage manufaturing faciliites, disrupt logistics and sourcing activities, and negatively affect employee health and communities where we operate More frequent and intense weather events and changing preciptation patterns are likely to affect the performance of grids and thermal plants while pushing up demand for cooling, damage fixed assets, disrupt logistics and sourcing activities, and negatively affect employee health and communities where we operate IMPACT DRIVER & NET ZERO FUTURE PLEDGING PROGRESS STEADFAST POLICY Resource Efficiency Opportunity More efficient production and distribution processes, reduced natural resource usage, continued use of recycling, and inclusion of recycled materials in our products such as reSoundTM R, ColorMatrix™ Capture™ Oxygen Scavenger, among others will contribute to increasing product revenues and reduced operating costs Resource efficiency efforts supported by capital allocation in NDC countries is more likely and may accelerate a path toward maximizing ROI and reducing operating costs Less regulatory and pressure to incentivize may cause gains from efforts to lag Energy Source Opportunity Use of greater external financing options, such as operating lease arrangements or energy performance shared savings contracts, to source lower emission-energy and new technologies, such as carbon capture, utilization & storage (CCUS), in our operations may reduce operating costs and maximize returns on investment Use of lower emission-sources of energy in operations will lower operating costs and contribute toward reductions of our scope 1 and 2 emissions and product carbon intensities Use of renewable energy, increased efficiency, and electrification initiatives will lower operating costs and contribute toward reductions of our scope 1 and 2 emissions and product carbon intensities. Avient joined the Alliance to End Plastic Waste as a founding member and is collaborating with over 65 member companies to promote infrastructure, education and engagement, innovation, and clean up effrots to keep plastic waste in the right place

2) Tax adjustments include the net tax impact from non-recurring income tax items, adjustments to uncertain tax position reserves and changes to valuation allowances. 10 Attachment 4 Avient Corporation Condensed Consolidated Balance Sheets (In millions) (Unaudited) March 31, 2023 December 31, 2022 ASSETS Current assets: Cash and cash equivalents $ 582.7 $ 641.1 Accounts receivable, net 484.4 440.6 Inventories, net 371.9 372.7 Other current assets 125.3 115.3 Total current assets 1,564.3 1,569.7 Property, net 1,045.7 1,049.2 Goodwill 1,689.7 1,671.9 Intangible assets, net 1,601.7 1,597.6 Other non-current assets 209.8 196.6 Total assets $ 6,111.2 $ 6,085.0 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Short-term debt $ 2.2 $ 2.2 Accounts payable 448.1 454.4 Accrued expenses and other current liabilities 386.9 412.8 Total current liabilities 837.2 869.4 Non-current liabilities: Long-term debt 2,177.7 2,176.7 Pension and other post-retirement benefits 66.2 67.2 Deferred income taxes 332.5 342.5 Other non-current liabilities 329.0 276.4 Total non-current liabilities 2,905.4 2,862.8 SHAREHOLDERS' EQUITY Avient shareholders’ equity 2,349.8 2,334.5 Noncontrolling interest 18.8 18.3 Total equity 2,368.6 2,352.8 Total liabilities and equity $ 6,111.2 $ 6,085.0 11 Attachment 5 Avient Corporation Condensed Consolidated Statements of Cash Flows (Unaudited) (In millions) Three Months Ended March 31, 2023 2022 Operating Activities Net income $ 20.4 $ 84.5 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 48.7 35.7 Accelerated depreciation 1.8 2.1 Share-based compensation expense 3.2 3.2 Changes in assets and liabilities, net of the effect of acquisitions: Increase in accounts receivable (40.2) (118.8) Decrease (increase) in inventories 3.8 (15.1) (Decrease) increase in accounts payable (9.9) 90.5 Accrued expenses and other assets and liabilities, net (50.0) (63.2) Net cash (used) provided by operating activities (22.2) 18.9 Investing activities Capital expenditures (20.3) (13.3) Net proceeds from divestiture 7.3 — Net cash used by investing activities (13.0) (13.3) Financing activities Purchase of common shares for treasury — (15.8) Cash dividends paid (22.5) (21.7) Repayment of long-term debt (0.8) (2.4) Other financing (2.3) (3.9) Net cash used by financing activities (25.6) (43.8) Effect of exchange rate changes on cash 2.4 (0.4) Decrease in cash and cash equivalents (58.4) (38.6) Cash and cash equivalents at beginning of year 641.1 601.2 Cash and cash equivalents at end of period $ 582.7 $ 562.6 12 Attachment 6 Avient Corporation Business Segment Operations (Unaudited) (In millions) Operating income and earnings before interest, taxes, depreciation and amortization (EBITDA) at the segment level does not include: special items as defined in Attachment 3; corporate general and administration costs that are not allocated to segments; intersegment sales and profit eliminations; share-based compensation costs; and certain other items that are not included in the measure of segment profit and loss that is reported to and reviewed by the chief operating decision maker.

In all of its activities, Avient puts high emphasis on environmental protection and safety. Assessment is made both before and after consideration of our mitigating activities. No, but we are actively considering verifying within the next two years C11.

It will also make sure that such planning will support Avient Group’s commercial strategies and economic activities in the UK. Approach with Her Majesty’s Revenue and Customs (“HMRC”) The Avient Group is committed to: • promoting a professional, collaborative, open, and transparent relationship with HMRC • discussing business activities and transactions with significant tax implications with HMRC in a timely fashion • engaging in timely dialogue with HMRC to respond to queries and information requests to ensure that HMRC is aware of how issues are progressing • working proactively with HMRC to resolve all tax disputes, and • making appropriate disclosures in tax returns, reports, and correspondence submitted to HMRC.

lang=En&n=FD9B0E51-1 https://ec.ss.ec.gc.ca/auth/en/Services General Information Substance List CAS RN Substance Name Releases Releases (Speciated VOCs) Disposals Recycling Unit NA ­ 01 Antimony (and its compounds) 0.0004 N/A N/A N/A tonnes NA ­ 02 Arsenic (and its compounds) 0.0007 N/A N/A N/A kg 103­23­1 Bis(2­ethylhexyl) adipate 0.0106 N/A N/A N/A tonnes 117­81­7 Bis(2­ethylhexyl) phthalate 0.0283 N/A N/A N/A tonnes 85­68­7 Butyl benzyl phthalate 0.0008 N/A N/A N/A tonnes NA ­ 14 Zinc (and its compounds) 0.0000 N/A N/A 0.0002 tonnes Applicable Programs CAS RN Substance Name NPRI ON MOE TRA ON MOE Reg 127/01 First report for  this substance to  the ON MOE TRA NA ­ 01 Antimony (and its compounds) Yes NA ­ 02 Arsenic (and its compounds) Yes 103­23­1 Bis(2­ethylhexyl) adipate Yes 117­81­7 Bis(2­ethylhexyl) phthalate Yes 85­68­7 Butyl benzyl phthalate Yes NA ­ 14 Zinc (and its compounds) Yes Position: EHS Manager Telephone: 5192150535 Email: brian.greer@polyone.com Contact Type Certifying Official Name: Najat Kamal Position: EHSQ specialist Telephone: 5148089920 Email: najat.kamal@polyone.com Number of employees: 45 Activities for Which the 20,000­Hour Employee Threshold Does Not Apply: None of the above Activities Relevant to Reporting Dioxins, Furans and Hexacholorobenzene: None of the above Activities Relevant to Reporting of Polycyclic Aromatic Hydrocarbons (PAHs): Wood preservation using creosote: No Is this the first time the facility is reporting to the NPRI (under current or past ownership): Is the facility controlled by another Canadian company or companies: Did the facility report under other environmental regulations or permits: Is the facility required to report one or more NPRI Part 4 substances (Criteria Air Contaminants): Was the facility shut down for more than one week during the year: Operating Schedule ­ Days of the Week: Mon, Tue, Wed, Thu, Fri Usual Number of Operating Hours per day: 24 Usual Daily Start Time (24h) (hh:mm): 00:00 General Information about the Substance ­ Releases and Transfers of the Substance CAS RN Substance Name Was the substance released on­site The substance will be reported as the sum of releases to all media (total of 1 tonne or less) 1 tonne or more of a Part 5 Substance (Speciated VOC) was released to air Antimony (and its compounds) NA ­ 02 Arsenic (and its 103­23­1 Bis(2­ethylhexyl) adipate 117­81­7 Bis(2­ethylhexyl) 85­68­7 Butyl benzyl NA ­ 14 Zinc (and its General Information about the Substance ­ Disposals and Off­site Transfers for Recycling CAS RN Substance Name Was the substance disposed of (on­site or off­ site), or transferred for treatment prior to final disposal Is the facility required to report on disposals of tailings and waste rock for the selected reporting period Was the substance transferred off­site for recycling Antimony (and its NA ­ 02 Arsenic (and its 103­23­1 Bis(2­ ethylhexyl) adipate 117­81­7 Bis(2­ ethylhexyl) 85­68­7 Butyl benzyl NA ­ 14 Zinc (and its General Information about the Substance ­ Nature of Activities CAS RN Substance Name Manufacture the Substance Process the Substance Otherwise Use of the Substance NA ­ 01 Antimony (and its compounds) For on­site use/processing As a reactant As a by­product NA ­ 02 Arsenic (and its compounds) For on­site use/processing As a reactant As a by­product 103­23­1 Bis(2­ethylhexyl) adipate For on­site use/processing As a reactant As a by­product 117­81­7 Bis(2­ethylhexyl) phthalate For on­site use/processing As a reactant As a by­product 85­68­7 Butyl benzyl phthalate For on­site use/processing As a reactant As a by­product NA ­ 14 Zinc (and its compounds) For on­site use/processing As a reactant As a by­product On­site Releases ­ Releases to air NA ­ 02 Arsenic (and its compounds) Stack or Point Releases O ­ Engineering Estimates 0.0000 kg NA ­ 14 Zinc (and its compounds) Stack or Point Releases O ­ Engineering Estimates 0.0000 tonnes On­site Releases ­ Releases to air ­ Total CAS RN Substance Name Total ­ Releases to Air NA ­ 02 Arsenic (and its compounds) 0.0000 kg NA ­ 14 Zinc (and its compounds) 0.0000 tonnes On­site Releases ­ Releases to land NA ­ 02 Arsenic (and its compounds) Other O ­ Engineering Estimates 0.0007 kg Onsite Releases ­ Nature of Other Land Release CAS RN Substance Name Nature of Other Land Release NA ­ 02 Arsenic (and its compounds) Landfill disposal CAS RN Substance Name Nature of Other Land Release On­site Releases ­ Releases to land ­ Total CAS RN Substance Name Total ­ Releases to Land NA ­ 02 Arsenic (and its compounds) 0.0007 kg Total Quantity Released (All Media) NA ­ 01 Antimony (and its compounds) Total Quantity Released O ­ Engineering Estimates 0.0004 tonnes 103­23­1 Bis(2­ethylhexyl) adipate Total Quantity Released O ­ Engineering Estimates 0.0106 tonnes 117­81­7 Bis(2­ethylhexyl) phthalate Total Quantity Released O ­ Engineering Estimates 0.0283 tonnes 85­68­7 Butyl benzyl phthalate Total Quantity Released O ­ Engineering Estimates 0.0008 tonnes On­site Releases ­ Total CAS RN Substance Name Total releases NA ­ 02 Arsenic (and its compounds) 0.0007 kg NA ­ 14 Zinc (and its compounds) 0.0000 tonnes On­site Releases ­ Quarterly Breakdown of Annual Releases CAS RN Substance Name Quarter 1 Quarter 2 Quarter 3 Quarter 4 NA ­ 01 Antimony (and its compounds) 25 25 25 25 NA ­ 02 Arsenic (and its compounds) 25 25 25 25 103­23­1 Bis(2­ethylhexyl) adipate 25 25 25 25 117­81­7 Bis(2­ethylhexyl) phthalate 25 25 25 25 85­68­7 Butyl benzyl phthalate 25 25 25 25 On­site Releases ­ Reasons for Changes in Quantities Released from Previous Year CAS RN Substance Name Reasons for Changes in Quantities from Previous Year Comments NA ­ 01 Antimony (and its compounds) No significant change (i.e.  Did the facility complete any pollution prevention activities in the current NPRI reporting year Report Submission and Electronic Certification NPRI ­ Electronic Statement of Certification Specify the language of correspondence English Comments (optional)   I hereby certify that I have exercised due diligence to ensure that the submitted information is true and complete. 

2) Tax adjustments include the net tax benefit/(expense) from one-time income tax items, adjustments to uncertain tax position reserves and deferred income tax valuation allowances. 10 Attachment 4 Avient Corporation Condensed Consolidated Balance Sheets (Unaudited) (In millions) Year Ended December 31, 2021 2020 ASSETS Current assets: Cash and cash equivalents $ 601.2 $ 649.5 Accounts receivable, net 642.3 516.6 Inventories, net 461.1 327.5 Other current assets 128.1 108.5 Total current assets 1,832.7 1,602.1 Property, net 676.1 694.9 Goodwill 1,286.4 1,308.1 Intangible assets, net 925.2 1,008.5 Operating lease assets, net 74.1 80.9 Other non-current assets 208.4 176.0 Total assets $ 5,002.9 $ 4,870.5 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Short-term and current portion of long-term debt $ 8.6 $ 18.6 Accounts payable 553.9 471.7 Current operating lease obligations 24.2 25.1 Accrued expenses and other current liabilities 359.6 285.6 Total current liabilities 946.3 801.0 Non-current liabilities: Long-term debt 1,850.3 1,854.0 Pension and other post-retirement benefits 100.0 115.0 Deferred income taxes 100.6 140.0 Non-current operating lease obligations 50.1 56.0 Other non-current liabilities 165.1 192.8 Total non-current liabilities 2,266.1 2,357.8 SHAREHOLDERS' EQUITY Avient shareholders’ equity 1,774.7 1,697.1 Noncontrolling interest 15.8 14.6 Total equity 1,790.5 1,711.7 Total liabilities and equity $ 5,002.9 $ 4,870.5 11 Attachment 5 Avient Corporation Condensed Consolidated Statements of Cash Flows (Unaudited) (In millions) Year Ended December 31, 2021 2020 Operating activities Net income $ 230.6 $ 133.4 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 144.2 111.8 Accelerated depreciation 1.7 3.2 Share-based compensation expense 11.2 11.3 Changes in assets and liabilities, net of the effect of acquisitions: Increase in accounts receivable (143.1) (4.6) (Increase) decrease in inventories (139.5) 40.2 Increase in accounts payable 95.3 78.4 (Decrease) increase in pension and other post-retirement benefits (10.9) 30.7 Increase in post-acquisition earnout liabilities — 1.0 Increase (decrease) in accrued expenses and other assets and liabilities, net 44.3 (3.7) Taxes paid on gain on divestiture — (142.0) Payment of post-acquisition date earnout liability — (38.1) Net cash provided by operating activities 233.8 221.6 Investing activities Capital expenditures (100.6) (63.7) Business acquisitions, net of cash acquired (47.6) (1,380.2) Net proceeds from divestiture — 7.1 Other investing activities (2.0) 5.2 Net cash used by investing activities (150.2) (1,431.6) Financing activities Debt offering proceeds — 650.0 Purchase of common shares for treasury (4.2) (22.4) Cash dividends paid (77.7) (71.3) Repayment of long-term debt (18.5) (7.8) Payments on withholding tax on share awards (10.7) (2.3) Debt financing costs — (9.5) Equity offering proceeds, net of underwriting discount and issuance costs — 496.1 Payment of acquisition date earnout liability — (50.8) Other financing activities (3.5) — Net cash (used) provided by financing activities (114.6) 982.0 Effect of exchange rate changes on cash (17.3) 12.8 Decrease in cash and cash equivalents (48.3) (215.2) Cash and cash equivalents at beginning of year 649.5 864.7 Cash and cash equivalents at end of year $ 601.2 $ 649.5 12 Attachment 6 Avient Corporation Business Segment Operations (Unaudited) (In millions) Operating income at the segment level does not include: special items as defined in Attachment 3; corporate general and administration costs that are not allocated to segments; intersegment sales and profit eliminations; share-based compensation costs; and certain other items that are not included in the measure of segment profit and loss that is reported to and reviewed by the chief operating decision maker.